name: tooluniverse-spatial-omics-analysis
description: Computational analysis framework for spatial multi-omics data integration. Given spatially variable genes (SVGs), spatial domain annotations, tissue type, and disease context from spatial transcriptomics/proteomics experiments (10x Visium, MERFISH, DBiTplus, SLIDE-seq, etc.), performs comprehensive biological interpretation including pathway enrichment, cell-cell interaction inference, druggable target identification, immune microenvironment characterization, and multi-modal integration. Produces a detailed markdown report with Spatial Omics Integration Score (0-100), domain-by-domain characterization, and validation recommendations. Uses 70+ ToolUniverse tools across 9 analysis phases. Use when users ask about spatial transcriptomics analysis, spatial omics interpretation, tissue heterogeneity, spatial gene expression patterns, tumor microenvironment mapping, tissue zonation, or cell-cell communication from spatial data.
Spatial Multi-Omics Analysis Pipeline
Comprehensive biological interpretation of spatial omics data. Transforms spatially variable genes (SVGs), domain annotations, and tissue context into actionable biological insights covering pathway enrichment, cell-cell interactions, druggable targets, immune microenvironment, and multi-modal integration.
KEY PRINCIPLES:
- Report-first approach - Create report file FIRST, then populate progressively
- Domain-by-domain analysis - Characterize each spatial region independently before comparison
- Gene-list-centric - Analyze user-provided SVGs and marker genes with ToolUniverse databases
- Biological interpretation - Go beyond statistics to explain biological meaning of spatial patterns
- Disease focus - Emphasize disease mechanisms and therapeutic opportunities when disease context is provided
- Evidence grading - Grade all evidence as T1 (human/clinical) to T4 (computational)
- Multi-modal thinking - Integrate RNA, protein, and metabolite information when available
- Validation guidance - Suggest experimental validation approaches for key findings
- Source references - Every statement must cite tool/database source
- Completeness checklist - Mandatory section showing analysis coverage
- English-first queries - Always use English terms in tool calls. Respond in user's language
When to Use This Skill
Apply when users:
- Provide spatially variable genes from spatial transcriptomics experiments
- Ask about biological interpretation of spatial domains/clusters
- Need pathway enrichment analysis of spatial gene expression data
- Want to understand cell-cell interactions from spatial data
- Ask about tumor microenvironment heterogeneity from spatial omics
- Need druggable targets in specific spatial regions
- Ask about tissue zonation patterns (liver, brain, kidney)
- Want to integrate spatial transcriptomics + proteomics data
- Ask about immune infiltration patterns from spatial data
- Need to compare healthy vs disease regions spatially
- Ask "What pathways are enriched in this tumor core vs tumor margin?"
- Ask "What cell-cell interactions occur in this spatial domain?"
NOT for (use other skills instead):
- Single gene interpretation without spatial context -> Use
tooluniverse-target-research
- Variant interpretation -> Use
tooluniverse-variant-interpretation
- Drug safety profiling -> Use
tooluniverse-adverse-event-detection
- Disease-only analysis without spatial data -> Use
tooluniverse-multiomic-disease-characterization
- GWAS analysis -> Use
tooluniverse-gwas-* skills
- Bulk RNA-seq (non-spatial) -> Use
tooluniverse-systems-biology
Input Parameters
| Parameter |
Required |
Description |
Example |
| svgs |
Yes |
Spatially variable genes (gene symbols) |
['EGFR', 'CDH1', 'VIM', 'MYC', 'CD3E'] |
| tissue_type |
Yes |
Tissue/organ type |
brain, liver, lung, breast, skin |
| technology |
No |
Spatial omics platform used |
10x Visium, MERFISH, DBiTplus, SLIDE-seq |
| disease_context |
No |
Disease if applicable |
breast cancer, Alzheimer disease, liver cirrhosis |
| spatial_domains |
No |
Dict mapping domain name to marker genes |
{'Tumor core': ['MYC','EGFR'], 'Stroma': ['VIM','COL1A1']} |
| cell_types |
No |
Cell types identified in deconvolution |
['Epithelial', 'T cell', 'Macrophage', 'Fibroblast'] |
| proteins |
No |
Proteins detected (if multi-modal) |
['CD3', 'CD8', 'PD-L1', 'Ki67'] |
| metabolites |
No |
Metabolites detected (if SpatialMETA) |
['glutamine', 'lactate', 'ATP'] |
Spatial Omics Integration Score (0-100)
Score Components
Data Completeness (0-30 points):
- SVGs provided (>10 genes): 5 points
- Disease context provided: 5 points
- Spatial domains defined: 5 points
- Cell type composition available: 5 points
- Multi-modal data (protein/metabolite): 5 points
- Literature context found: 5 points
Biological Insight (0-40 points):
- Significant pathway enrichment (FDR < 0.05): 10 points
- Cell-cell interaction predictions: 10 points
- Disease mechanism identified: 10 points
- Druggable targets found in disease regions: 10 points
Evidence Quality (0-30 points):
- Cross-database validation (gene found in 3+ databases): 10 points
- Clinical validation (approved drugs for spatial targets): 10 points
- Literature support (PubMed evidence for spatial patterns): 10 points
Score Interpretation
| Score |
Tier |
Interpretation |
| 80-100 |
Excellent |
Comprehensive spatial characterization, strong biological insights, druggable targets identified |
| 60-79 |
Good |
Good pathway and interaction analysis, some disease/therapeutic context |
| 40-59 |
Moderate |
Basic enrichment complete, limited spatial domain comparison or interaction analysis |
| 0-39 |
Limited |
Minimal data, gene-level annotation only |
Evidence Grading System
| Tier |
Symbol |
Criteria |
Examples |
| T1 |
[T1] |
Direct human evidence, clinical proof |
FDA-approved drug for spatial target, validated biomarker |
| T2 |
[T2] |
Experimental evidence |
Validated spatial pattern in literature, known ligand-receptor pair |
| T3 |
[T3] |
Computational/database evidence |
PPI network prediction, pathway enrichment, expression correlation |
| T4 |
[T4] |
Annotation/prediction only |
GO annotation, text-mined association, predicted interaction |
Report Template
Create this file structure at the start: {tissue}_{disease}_spatial_omics_report.md
# Spatial Multi-Omics Analysis Report: {Tissue Type}
**Report Generated**: {date}
**Technology**: {platform}
**Tissue**: {tissue_type}
**Disease Context**: {disease or "Normal tissue"}
**Total SVGs Analyzed**: {count}
**Spatial Domains**: {count}
**Spatial Omics Integration Score**: (to be calculated)
---
## Executive Summary
(2-3 sentence synthesis of key spatial findings - fill after all phases complete)
---
## 1. Tissue & Disease Context
### Tissue Information
| Property | Value | Source |
|----------|-------|--------|
| Tissue type | | |
| Disease | | |
| Expected cell types | | HPA |
### Disease Identifiers (if applicable)
| System | ID | Source |
|--------|-----|--------|
**Sources**: (tools used)
---
## 2. Spatially Variable Gene Characterization
### 2.1 Gene ID Resolution
| Gene Symbol | Ensembl ID | Entrez ID | UniProt | Function | Source |
|-------------|------------|-----------|---------|----------|--------|
### 2.2 Tissue Expression Patterns
| Gene | Tissue Expression | Specificity | Source |
|------|-------------------|-------------|--------|
### 2.3 Subcellular Localization
| Gene | Location | Confidence | Source |
|------|----------|------------|--------|
### 2.4 Disease Associations
| Gene | Disease | Score | Evidence | Source |
|------|---------|-------|----------|--------|
**Sources**: (tools used)
---
## 3. Pathway Enrichment Analysis
### 3.1 STRING Functional Enrichment
| Category | Term | Description | P-value | FDR | Genes | Source |
|----------|------|-------------|---------|-----|-------|--------|
### 3.2 Reactome Pathway Analysis
| Pathway ID | Name | P-value | FDR | Genes Found | Total Genes | Source |
|------------|------|---------|-----|-------------|-------------|--------|
### 3.3 GO Biological Processes
| GO Term | Description | P-value | FDR | Genes | Source |
|---------|-------------|---------|-----|-------|--------|
### 3.4 GO Molecular Functions
| GO Term | Description | P-value | FDR | Genes | Source |
|---------|-------------|---------|-----|-------|--------|
### 3.5 GO Cellular Components
| GO Term | Description | P-value | FDR | Genes | Source |
|---------|-------------|---------|-----|-------|--------|
### Pathway Summary
- Top enriched pathways:
- Key biological processes:
- Spatial pathway implications:
**Sources**: (tools used)
---
## 4. Spatial Domain Characterization
### Domain: {domain_name}
#### Marker Genes
| Gene | Function | Pathways | Source |
|------|----------|----------|--------|
#### Enriched Pathways (domain-specific)
| Pathway | P-value | FDR | Genes | Source |
|---------|---------|-----|-------|--------|
#### Cell Type Signature
| Cell Type | Marker Genes Present | Confidence |
|-----------|---------------------|------------|
#### Biological Interpretation
(Narrative interpretation of this domain)
(Repeat for each domain)
### 4.N Domain Comparison
| Feature | Domain 1 | Domain 2 | Domain 3 |
|---------|----------|----------|----------|
| Top pathway | | | |
| Cell types | | | |
| Disease relevance | | | |
**Sources**: (tools used)
---
## 5. Cell-Cell Interaction Inference
### 5.1 Protein-Protein Interactions (STRING)
| Protein A | Protein B | Score | Type | Source |
|-----------|-----------|-------|------|--------|
### 5.2 Ligand-Receptor Pairs
| Ligand | Receptor | Domain (Ligand) | Domain (Receptor) | Evidence | Source |
|--------|----------|-----------------|-------------------|----------|--------|
### 5.3 Signaling Pathways
| Pathway | Components in Data | Spatial Distribution | Source |
|---------|--------------------|---------------------|--------|
### 5.4 Interaction Network Summary
- Key interaction hubs:
- Cross-domain interactions:
- Predicted cell-cell communication axes:
**Sources**: (tools used)
---
## 6. Disease & Therapeutic Context
### 6.1 Disease Gene Overlap
| Gene | Disease Association Score | Evidence Type | Source |
|------|--------------------------|---------------|--------|
### 6.2 Druggable Targets in Spatial Domains
| Gene | Domain | Tractability | Modality | Approved Drugs | Source |
|------|--------|-------------|----------|----------------|--------|
### 6.3 Drug Mechanisms Relevant to Spatial Targets
| Drug | Target | Mechanism | Phase | Source |
|------|--------|-----------|-------|--------|
### 6.4 Clinical Trials
| NCT ID | Title | Target Gene | Phase | Status | Source |
|--------|-------|-------------|-------|--------|--------|
### Therapeutic Summary
- Druggable genes in disease regions:
- Approved therapies:
- Pipeline drugs:
- Novel opportunities:
**Sources**: (tools used)
---
## 7. Multi-Modal Integration
### 7.1 Protein-RNA Concordance (if protein data available)
| Gene/Protein | RNA Pattern | Protein Pattern | Concordance | Source |
|-------------|-------------|-----------------|-------------|--------|
### 7.2 Subcellular Context
| Gene | mRNA Location (spatial) | Protein Location (HPA) | Concordance | Source |
|------|------------------------|----------------------|-------------|--------|
### 7.3 Metabolic Context (if metabolomics available)
| Gene | Metabolic Pathway | Metabolites Detected | Spatial Pattern | Source |
|------|-------------------|---------------------|-----------------|--------|
**Sources**: (tools used)
---
## 8. Immune Microenvironment (if relevant)
### 8.1 Immune Cell Markers
| Cell Type | Marker Genes | Spatial Domain | Source |
|-----------|-------------|----------------|--------|
### 8.2 Immune Checkpoint Expression
| Checkpoint | Gene | Expression Pattern | Source |
|------------|------|--------------------|--------|
### 8.3 Tumor-Immune Interface (if cancer)
| Feature | Finding | Evidence | Source |
|---------|---------|----------|--------|
### Immune Summary
- Immune infiltration pattern:
- Key immune checkpoints:
- Immunotherapy implications:
**Sources**: (tools used)
---
## 9. Literature & Validation Context
### 9.1 Literature Evidence
| PMID | Title | Relevance | Year | Source |
|------|-------|-----------|------|--------|
### 9.2 Known Spatial Patterns
(Known tissue architecture/zonation from literature)
### 9.3 Validation Recommendations
| Priority | Gene/Target | Method | Rationale |
|----------|-------------|--------|-----------|
| High | | IHC / smFISH | |
| Medium | | IF / ISH | |
**Sources**: (tools used)
---
## Spatial Omics Integration Score
| Component | Points | Max | Details |
|-----------|--------|-----|---------|
| SVGs provided | | 5 | |
| Disease context | | 5 | |
| Spatial domains | | 5 | |
| Cell types | | 5 | |
| Multi-modal data | | 5 | |
| Literature context | | 5 | |
| Pathway enrichment | | 10 | |
| Cell-cell interactions | | 10 | |
| Disease mechanism | | 10 | |
| Druggable targets | | 10 | |
| Cross-database validation | | 10 | |
| Clinical validation | | 10 | |
| Literature support | | 10 | |
| **TOTAL** | | **100** | |
**Score**: XX/100 - [Tier]
---
## Completeness Checklist
- [ ] Gene ID resolution complete
- [ ] Tissue expression patterns analyzed (HPA)
- [ ] Subcellular localization checked (HPA)
- [ ] Pathway enrichment complete (STRING + Reactome)
- [ ] GO enrichment complete (BP + MF + CC)
- [ ] Spatial domains characterized individually
- [ ] Domain comparison performed
- [ ] Protein-protein interactions analyzed (STRING)
- [ ] Ligand-receptor pairs identified
- [ ] Disease associations checked (OpenTargets)
- [ ] Druggable targets identified (OpenTargets tractability)
- [ ] Drug mechanisms reviewed
- [ ] Multi-modal integration performed (if data available)
- [ ] Immune microenvironment characterized (if relevant)
- [ ] Literature search completed
- [ ] Validation recommendations provided
- [ ] Spatial Omics Integration Score calculated
- [ ] Executive summary written
- [ ] All sections have source citations
---
## References
### Data Sources Used
| # | Tool | Parameters | Section | Items Retrieved |
|---|------|------------|---------|-----------------|
### Database Versions
- OpenTargets: (current)
- STRING: v12.0
- Reactome: (current)
- HPA: (current)
- GTEx: v10
Phase 0: Input Processing & Disambiguation (ALWAYS FIRST)
Objective: Parse user input, resolve tissue/disease identifiers, establish analysis context.
Tools Used
OpenTargets_get_disease_id_description_by_name (if disease context provided):
- Input:
diseaseName (string) - Disease name
- Output:
{data: {search: {hits: [{id, name, description}]}}}
- Use: Get MONDO/EFO IDs for disease queries
OpenTargets_get_disease_description_by_efoId:
- Input:
efoId (string) - Disease ID (e.g., MONDO_0007254)
- Output:
{data: {disease: {id, name, description, dbXRefs}}}
- Use: Get full disease description
HPA_search_genes_by_query (tissue cell type context):
- Input:
query (string) - Search term
- Output: List of gene entries matching query
- Use: Verify tissue-relevant genes
Workflow
- Parse SVG list from user input (ensure valid gene symbols)
- Identify tissue type and map to standard ontology term
- If disease provided, resolve to MONDO/EFO ID using OpenTargets
- Get disease description and cross-references
- Determine analysis scope:
- Cancer? -> Include immune microenvironment, somatic mutations, druggable targets
- Neurological? -> Include brain region specificity, neuronal markers
- Metabolic? -> Include metabolic zonation, enzyme distribution
- Normal tissue? -> Focus on tissue architecture and cell type composition
- Set up report file with header information
Decision Logic
- Cancer tissue: Enable immune microenvironment phase, CIViC/cBioPortal queries, immuno-oncology analysis
- Normal tissue: Skip disease phases, focus on tissue zonation and cell type composition
- Liver/kidney/brain: Enable zonation-specific analysis
- No disease context: Proceed with tissue biology only
- Small gene list (<20): Warn about limited enrichment power, emphasize gene-level analysis
- Large gene list (>500): Suggest filtering to top SVGs by significance before enrichment
Phase 1: Gene Characterization
Objective: Resolve gene identifiers, annotate functions, tissue specificity, and subcellular localization.
Tools Used
MyGene_query_genes (gene ID resolution):
- Input:
query (string) - Gene symbol
- Output:
{hits: [{_id, symbol, name, ensembl: {gene}, entrezgene}]}
- Use: Resolve gene symbol to Ensembl ID, Entrez ID
- NOTE: First hit may not be exact match - filter by
symbol field
UniProt_get_function_by_accession (gene function):
- Input:
accession (string) - UniProt accession
- Output: List of function description strings
- Use: Get protein function annotation
UniProt_get_subcellular_location_by_accession (protein localization):
- Input:
accession (string)
- Output: Subcellular location information
- Use: Where the protein is located in the cell
HPA_get_subcellular_location (validated localization):
- Input:
gene_name (string) - Gene symbol
- Output:
{gene_name, main_locations: [], additional_locations: [], location_summary}
- Use: Experimentally validated protein subcellular location
HPA_get_rna_expression_by_source (tissue expression):
- Input:
gene_name (string), source_type (string: 'tissue'), source_name (string)
- Output:
{data: {gene_name, source_type, source_name, expression_value, expression_level}}
- Use: Check expression in the specific tissue of interest
- NOTE: All 3 parameters are REQUIRED
HPA_get_comprehensive_gene_details_by_ensembl_id (full HPA data):
- Input:
ensembl_id (string), include_isoforms (bool), include_images (bool), include_antibodies (bool), include_expression (bool) - ALL 5 parameters REQUIRED
- Output:
{ensembl_id, gene_name, uniprot_ids, summary, protein_classes, tissue_expression, cell_line_expression, ...}
- Use: One-stop gene characterization from HPA
- NOTE: Use
include_expression=True for tissue data; set others to False for faster response
HPA_get_cancer_prognostics_by_gene (cancer prognosis):
- Input:
ensembl_id (string) - Ensembl gene ID (NOT gene_name)
- Output:
{gene_name, prognostic_cancers_count, prognostic_summary: [{cancer_type, prognostic_type, p_value}]}
- Use: Prognostic significance in cancer (if cancer context)
UniProtIDMap_gene_to_uniprot (ID mapping):
- Input:
gene_name (string), organism (string, default 'human')
- Output: UniProt accession for the gene
- Use: Map gene symbol to UniProt accession
Workflow
- For each SVG (batch if >20, sample top genes):
a. Query MyGene to get Ensembl ID, Entrez ID
b. Map to UniProt accession
c. Get subcellular location from HPA
d. Get tissue expression from HPA
e. If cancer: check cancer prognostics
- Compile gene characterization table
- Identify genes with tissue-specific expression
- Note genes with nuclear vs membrane vs secreted localization (relevant for spatial patterns)
Batch Strategy for Large Gene Lists
- 10-50 genes: Characterize all individually
- 50-200 genes: Characterize top 50 by priority (known disease genes first), summarize rest
- 200+ genes: Characterize top 30, use enrichment for the full list
- Always run pathway enrichment on the FULL list regardless
Phase 2: Pathway & Functional Enrichment
Objective: Identify biological pathways and functions enriched in SVGs and per-domain gene sets.
Tools Used
STRING_functional_enrichment (primary enrichment):
- Input:
protein_ids (array of gene symbols), species (int, 9606 for human)
- Output:
{status: 'success', data: [{category, term, number_of_genes, number_of_genes_in_background, p_value, fdr, description, inputGenes, preferredNames}]}
- Use: Comprehensive enrichment across GO, KEGG, Reactome, COMPARTMENTS, DISEASES
- Categories:
Process (GO:BP), Function (GO:MF), Component (GO:CC), KEGG, Reactome, COMPARTMENTS, DISEASES, Keyword, PMID
- NOTE: This is the PRIMARY enrichment tool. Returns all categories in one call
ReactomeAnalysis_pathway_enrichment (Reactome-specific):
- Input:
identifiers (string, space-separated gene symbols, NOT array)
- Output:
{data: {token, pathways_found, pathways: [{pathway_id, name, p_value, fdr, entities_found, entities_total}]}}
- Use: Detailed Reactome pathway analysis with hierarchy
- NOTE: identifiers is a SPACE-SEPARATED STRING, not array
Reactome_map_uniprot_to_pathways (individual gene):
- Input:
id (string) - UniProt accession
- Output: Plain list of pathway objects (no data wrapper)
- Use: Map individual proteins to Reactome pathways
GO_get_annotations_for_gene (individual gene GO):
- Input:
gene_id (string) - Gene symbol or ID
- Output: Plain list of GO annotation objects
- Use: Get GO annotations for individual genes
kegg_search_pathway (KEGG pathway search):
- Input:
query (string) - Pathway name or keyword
- Output: Pathway search results
- Use: Find KEGG pathways relevant to spatial findings
WikiPathways_search (WikiPathways):
- Input:
query (string) - Search term
- Output: WikiPathways search results
- Use: Additional pathway context
Workflow
- Global SVG enrichment: Run STRING_functional_enrichment on ALL SVGs
- Filter results by FDR < 0.05
- Separate by category (Process, Function, Component, KEGG, Reactome)
- Report top 10-15 per category
- Reactome detailed analysis: Run ReactomeAnalysis_pathway_enrichment
- Report top pathways with FDR < 0.05
- Per-domain enrichment (if spatial domains provided):
- Run STRING_functional_enrichment on each domain's gene set
- Compare enriched pathways across domains
- Identify domain-specific vs shared pathways
- Compile pathway tables: Merge results from all enrichment tools
Enrichment Interpretation
- Signaling pathways (RTK, Wnt, Notch, Hedgehog): Cell-cell communication
- Metabolic pathways: Tissue metabolic zonation
- Immune pathways: Immune infiltration/exclusion
- ECM/adhesion pathways: Tissue structure and remodeling
- Cell cycle/proliferation: Growth zones
- Apoptosis/stress: Damage zones
Phase 3: Spatial Domain Characterization
Objective: Characterize each spatial domain biologically and compare between domains.
Tools Used
Uses the same tools as Phase 2 (STRING_functional_enrichment, ReactomeAnalysis) applied per-domain, plus:
HPA_get_biological_processes_by_gene (per-gene processes):
- Input:
gene_name (string)
- Output: Biological processes associated with the gene
- Use: Annotate domain marker genes
HPA_get_protein_interactions_by_gene (gene interactions):
- Input:
gene_name (string)
- Output: Known protein interaction partners
- Use: Build domain-specific interaction context
Workflow
- For each spatial domain:
a. Get marker gene list
b. Run STRING_functional_enrichment on domain genes
c. Identify top pathways, GO terms
d. Assign likely cell type(s) based on marker genes:
- Epithelial: CDH1, EPCAM, KRT18, KRT19
- Mesenchymal/Fibroblast: VIM, COL1A1, COL3A1, FAP, ACTA2
- Immune T cell: CD3E, CD3D, CD4, CD8A, CD8B
- Immune B cell: CD19, CD20 (MS4A1), CD79A
- Macrophage: CD68, CD163, CSF1R
- Endothelial: PECAM1, VWF, CDH5
- Neuronal: SNAP25, SYP, MAP2, NEFL
- Hepatocyte: ALB, HNF4A, CYP3A4
e. Generate biological interpretation narrative
- Compare domains:
- Differential pathways
- Unique vs shared genes
- Disease-relevant vs homeostatic regions
- Transition zones (shared genes between adjacent domains)
Cell Type Assignment Rules
When user does not provide cell type annotations, infer from marker genes:
- Check each gene against known cell type markers
- Use HPA tissue/cell type expression data for validation
- Report confidence level (high: 3+ markers match, medium: 2 markers, low: 1 marker)
Phase 4: Cell-Cell Interaction Inference
Objective: Predict cell-cell communication from spatial gene expression patterns.
Tools Used
STRING_get_interaction_partners (PPI network):
- Input:
protein_ids (array), species (int, 9606), limit (int), confidence_score (float, 0.7)
- Output:
{status: 'success', data: [{preferredName_A, preferredName_B, score, nscore, fscore, pscore, ascore, escore, dscore, tscore}]}
- Use: Find protein-protein interactions among SVGs
- Score types: nscore=neighborhood, fscore=fusion, pscore=phylogenetic, ascore=coexpression, escore=experimental, dscore=database, tscore=textmining
STRING_get_protein_interactions (pairwise interactions):
- Input:
protein_ids (array), species (int, 9606)
- Output: Interaction data between specified proteins
- Use: Get interactions within a specific gene set
intact_search_interactions (IntAct database):
- Input:
query (string), max (int)
- Output: Interaction data from IntAct
- Use: Complement STRING with IntAct interactions
Reactome_get_interactor (Reactome interactions):
- Input: Protein/gene identifier
- Output: Reactome interaction data
- Use: Pathway-level interaction context
DGIdb_get_drug_gene_interactions (drug-gene interactions):
- Input:
genes (array of strings)
- Output: Drug-gene interaction data
- Use: Identify druggable interaction nodes
Ligand-Receptor Analysis
Known ligand-receptor pairs to check in SVG list:
- Growth factors: EGF-EGFR, HGF-MET, VEGF-KDR, FGF-FGFR, PDGF-PDGFRA/B
- Cytokines: TNF-TNFR, IL6-IL6R, IFNG-IFNGR, TGFB1-TGFBR1/2
- Chemokines: CXCL12-CXCR4, CCL2-CCR2, CXCL10-CXCR3
- Immune checkpoints: CD274(PD-L1)-PDCD1(PD-1), CD80/CD86-CTLA4, LGALS9-HAVCR2(TIM-3)
- Notch signaling: DLL1/3/4-NOTCH1/2/3/4, JAG1/2-NOTCH1/2
- Wnt signaling: WNT ligands-FZD receptors
- Adhesion: CDH1-CDH1 (homotypic), ITGA/B integrins-ECM
- Hedgehog: SHH-PTCH1
Workflow
- Run STRING_get_interaction_partners on all SVGs
- Filter interactions with score > 0.7
- Identify hub genes (most connections)
- Check for known ligand-receptor pairs in gene list
- Cross-reference with spatial domain assignments
- Identify potential cross-domain signaling
- Build interaction network:
- Intra-domain interactions (within same spatial region)
- Inter-domain interactions (between different regions)
- Identify signaling axes (e.g., tumor-stroma, immune-tumor)
- Map interactions to Reactome signaling pathways
Phase 5: Disease & Therapeutic Context
Objective: Connect spatial findings to disease mechanisms and identify druggable targets.
Tools Used
OpenTargets_get_associated_targets_by_disease_efoId (disease genes):
- Input:
efoId (string), size (int)
- Output:
{data: {disease: {associatedTargets: {count, rows: [{target: {id, approvedSymbol}, score}]}}}}
- Use: Get disease-associated genes, overlap with SVGs
OpenTargets_get_target_tractability_by_ensemblID (druggability):
- Input:
ensemblId (string)
- Output: Tractability data (small molecule, antibody, other modalities)
- Use: Assess if spatial targets are druggable
OpenTargets_get_associated_drugs_by_target_ensemblID (drugs for target):
- Input:
ensemblId (string), size (int)
- Output: Drug data for the target
- Use: Find approved/clinical drugs targeting spatial genes
OpenTargets_get_drug_mechanisms_of_action_by_chemblId (drug mechanism):
- Input:
chemblId (string)
- Output: Mechanism of action data
- Use: Understand how drugs act on spatial targets
OpenTargets_target_disease_evidence (evidence linking target to disease):
- Input:
ensemblId (string), efoId (string)
- Output: Evidence items linking target to disease
- Use: Specific evidence for each spatial gene in disease
clinical_trials_search (clinical trials):
- Input:
action = "search_studies", condition (string), intervention (string), limit (int)
- Output:
{total_count, studies: [{nctId, title, status, conditions}]}
- Use: Find clinical trials for spatial targets
- NOTE:
action MUST be "search_studies"
DGIdb_get_gene_druggability (druggability categories):
- Input:
genes (array of strings)
- Output:
{data: {genes: {nodes: [{name, geneCategories: [{name}]}]}}}
- Use: Classify genes as druggable, kinase, GPCR, etc.
civic_search_genes (CIViC cancer evidence, if cancer):
- Input: (no filter by name)
- Output: Gene list from CIViC
- Use: Check if SVGs have CIViC clinical evidence
Workflow
- Disease gene overlap (if disease context provided):
a. Get disease-associated targets from OpenTargets
b. Intersect with SVGs
c. For overlapping genes, get specific evidence
- Druggable target identification:
a. Run DGIdb_get_gene_druggability on all SVGs
b. For druggable genes, check OpenTargets tractability
c. Get approved drugs for druggable spatial targets
- Clinical trials:
a. Search for trials targeting spatial genes in the disease context
b. Prioritize trials for genes in disease-enriched spatial domains
- Cancer-specific (if cancer):
a. Check CIViC for clinical evidence
b. Get mutation prevalence from cBioPortal (if specific mutations known)
c. Check immune checkpoint genes in spatial data
Phase 6: Multi-Modal Integration
Objective: Integrate protein, RNA, and metabolite spatial data when available.
Tools Used
HPA_get_subcellular_location (protein localization):
- Input:
gene_name (string)
- Output:
{gene_name, main_locations, additional_locations, location_summary}
- Use: Compare mRNA spatial pattern with protein subcellular location
HPA_get_rna_expression_in_specific_tissues (tissue RNA):
- Input:
ensembl_id (string), tissue_name (string)
- Output: Expression data for specific tissue
- Use: Validate spatial expression against bulk tissue data
Reactome_map_uniprot_to_pathways (metabolic pathways):
- Input:
id (string) - UniProt accession
- Output: List of pathways
- Use: Map genes to metabolic pathways for metabolomics integration
kegg_get_pathway_info (KEGG pathway details):
- Input:
pathway_id (string) - KEGG pathway ID
- Output: Pathway information including metabolites
- Use: Link spatial genes to metabolic pathways and metabolites
Workflow
- RNA-Protein concordance (if protein data provided):
a. For each gene with both RNA and protein data:
- Compare spatial RNA pattern with protein detection
- Check HPA for known post-transcriptional regulation
- Note concordant (expected) vs discordant (interesting) patterns
- Subcellular context:
a. Map spatial RNA localization to protein subcellular location (HPA)
b. Secreted proteins -> likely paracrine signaling
c. Membrane proteins -> cell surface markers
d. Nuclear proteins -> transcription factors
- Metabolic integration (if metabolomics available):
a. Map genes to metabolic pathways (Reactome, KEGG)
b. Link detected metabolites to enzyme-encoding genes
c. Identify spatial metabolic heterogeneity
d. Check for known metabolic zonation patterns
Phase 7: Immune Microenvironment (Cancer/Inflammation)
Objective: Characterize immune cell composition and checkpoint expression in spatial context.
Conditions for Activation
Only execute if:
- Disease context is cancer, autoimmune, or inflammatory
- SVGs include immune markers (CD3E, CD8A, CD68, CD163, etc.)
- User specifically asks about immune patterns
Tools Used
STRING_functional_enrichment (immune pathway enrichment):
- Applied to immune-relevant SVGs
- Filter for immune-related GO terms and pathways
OpenTargets_get_target_tractability_by_ensemblID (checkpoint druggability):
- Applied to immune checkpoint genes
- Check for approved immunotherapies
iedb_search_epitopes (epitope data):
- Input:
organism_name (string), source_antigen_name (string)
- Output:
{status, data, count}
- Use: Check if spatial antigens have known epitopes
Immune Cell Markers Reference
| Cell Type |
Key Markers |
Extended Markers |
| CD8+ T cell |
CD8A, CD8B |
GZMA, GZMB, PRF1, IFNG |
| CD4+ T cell |
CD4 |
IL2, IL4, IL17A, FOXP3 (Treg) |
| Regulatory T cell |
FOXP3, IL2RA |
CTLA4, TIGIT |
| B cell |
CD19, MS4A1, CD79A |
IGHG1, IGHM |
| Plasma cell |
SDC1 (CD138), XBP1 |
IGHG1, MZB1 |
| M1 Macrophage |
CD68, NOS2, TNF |
IL1B, CXCL10 |
| M2 Macrophage |
CD68, CD163, MRC1 |
ARG1, IL10 |
| Dendritic cell |
ITGAX (CD11c), HLA-DRA |
CD80, CD86 |
| NK cell |
NCAM1 (CD56), NKG7 |
GNLY, KLRD1 |
| Neutrophil |
FCGR3B, CXCR2 |
S100A8, S100A9 |
| Mast cell |
KIT, TPSAB1 |
CPA3, HDC |
Immune Checkpoint Reference
| Checkpoint |
Gene |
Ligand |
Therapeutic Antibody |
| PD-1/PD-L1 |
PDCD1/CD274 |
CD274, PDCD1LG2 |
Pembrolizumab, Nivolumab, Atezolizumab |
| CTLA-4 |
CTLA4 |
CD80, CD86 |
Ipilimumab |
| TIM-3 |
HAVCR2 |
LGALS9 |
Sabatolimab |
| LAG-3 |
LAG3 |
HLA class II |
Relatlimab |
| TIGIT |
TIGIT |
PVR, PVRL2 |
Tiragolumab |
| VISTA |
VSIR |
PSGL1 |
- |
Workflow
- Identify immune-related SVGs from marker reference
- Classify immune cell types present per spatial domain
- Check immune checkpoint expression
- Assess immune infiltration patterns:
- Hot (T cell infiltrated) vs Cold (immune desert) vs Excluded
- Identify potential immunotherapy targets
- Check for tertiary lymphoid structures (B cell + T cell clusters)
Phase 8: Literature & Validation Context
Objective: Provide literature evidence for spatial findings and suggest validation experiments.
Tools Used
PubMed_search_articles (literature search):
- Input:
query (string), max_results (int)
- Output: List of
[{pmid, title, authors, journal, pub_date, doi}]
- Use: Find published evidence for spatial patterns
openalex_literature_search (broader literature):
- Input:
query (string), per_page (int)
- Output: List of works with titles, DOIs, abstracts
- Use: Complement PubMed with preprints and broader coverage
Literature Search Strategy
- Tissue + spatial:
"{tissue} spatial transcriptomics" - e.g., "liver spatial transcriptomics"
- Disease + spatial:
"{disease} spatial omics" - e.g., "breast cancer spatial transcriptomics"
- Gene + tissue:
"{top_gene} {tissue} expression" for key SVGs
- Zonation (if relevant):
"{tissue} zonation gene expression"
- Technology:
"{technology} {tissue}" - e.g., "Visium breast cancer"
Validation Recommendations Template
| Priority |
Target |
Method |
Rationale |
Feasibility |
| High |
Key SVG |
smFISH / RNAscope |
Validate spatial pattern at single-molecule level |
Medium |
| High |
Druggable target |
IHC on serial sections |
Confirm protein expression in spatial domain |
High |
| High |
Ligand-receptor pair |
Proximity ligation assay (PLA) |
Confirm physical interaction at tissue level |
Medium |
| Medium |
Domain markers |
Multiplexed IF (CODEX/IBEX) |
Validate multiple markers simultaneously |
Low-Medium |
| Medium |
Pathway |
Spatial metabolomics (MALDI/DESI) |
Confirm metabolic pathway activity |
Low |
| Low |
Novel interaction |
Co-culture + conditioned media |
Functional validation of predicted interaction |
Medium |
Workflow
- Search PubMed for tissue + disease + spatial transcriptomics
- Search for known spatial patterns in the tissue type
- Cross-reference findings with published spatial atlas data
- Generate validation recommendations based on:
- Novelty of finding (novel patterns need more validation)
- Clinical relevance (druggable targets prioritized)
- Technical feasibility
- Cite relevant methodology papers for each validation approach
Tool Parameter Reference (CRITICAL)
Verified Parameter Names
| Tool |
Parameter |
CORRECT |
Common MISTAKE |
Notes |
MyGene_query_genes |
query |
query |
q |
Filter results by symbol field |
STRING_functional_enrichment |
identifiers |
protein_ids (array) |
identifiers |
Also needs species=9606 |
STRING_get_interaction_partners |
identifiers |
protein_ids (array) |
identifiers |
limit, confidence_score optional |
ReactomeAnalysis_pathway_enrichment |
genes |
identifiers (string) |
Array |
SPACE-SEPARATED string, NOT array |
HPA_get_subcellular_location |
gene |
gene_name |
ensembl_id |
Uses gene symbol |
HPA_get_cancer_prognostics_by_gene |
gene |
ensembl_id |
gene_name |
Uses Ensembl ID, NOT symbol |
HPA_get_rna_expression_by_source |
params |
gene_name, source_type, source_name |
- |
ALL 3 required |
HPA_get_rna_expression_in_specific_tissues |
gene |
ensembl_id |
gene_name |
Uses Ensembl ID |
OpenTargets_get_target_tractability_by_ensemblID |
target |
ensemblId |
ensemblID |
camelCase |
OpenTargets_get_associated_drugs_by_target_ensemblID |
target |
ensemblId, size |
- |
Both REQUIRED |
OpenTargets_get_associated_targets_by_disease_efoId |
disease |
efoId |
diseaseId |
Returns {data: {disease: {associatedTargets}}} |
DGIdb_get_gene_druggability |
genes |
genes (array) |
gene_name |
Array of strings |
DGIdb_get_drug_gene_interactions |
genes |
genes (array) |
gene_name |
Array of strings |
clinical_trials_search |
action |
action='search_studies' |
Missing action |
action is REQUIRED |
ensembl_lookup_gene |
species |
species='homo_sapiens' |
No species |
REQUIRED parameter |
| GTEx tools |
operation |
operation (SOAP) |
Missing |
All GTEx tools need operation parameter |
HPA_get_comprehensive_gene_details_by_ensembl_id |
all params |
ALL 5 required: ensembl_id, include_isoforms, include_images, include_antibodies, include_expression |
Missing booleans |
Set booleans to False except expression |
| GTEx tools |
gencode |
gencode_id (array) |
gene_id |
Requires versioned GENCODE ID |
Response Format Reference
| Tool |
Response Format |
Key Fields |
STRING_functional_enrichment |
{status, data: [{category, term, description, p_value, fdr, inputGenes}]} |
Filter by FDR < 0.05 |
ReactomeAnalysis_pathway_enrichment |
{data: {pathways: [{pathway_id, name, p_value, fdr, entities_found, entities_total}]}} |
Top 20 returned |
STRING_get_interaction_partners |
{status, data: [{preferredName_A, preferredName_B, score}]} |
Score > 0.7 for high confidence |
MyGene_query_genes |
{hits: [{_id, symbol, name, ensembl: {gene}, entrezgene}]} |
Filter by exact symbol match |
HPA_get_subcellular_location |
{gene_name, main_locations: [], additional_locations: [], location_summary} |
Dire |
…(truncated)
1---2name: spatial-omics-analysis3description: ToolUniverse workflow — Spatial Omics Analysis4---56---7name: tooluniverse-spatial-omics-analysis8description: Computational analysis framework for spatial multi-omics data integration. Given spatially variable genes (SVGs), spatial domain annotations, tissue type, and disease context from spatial transcriptomics/proteomics experiments (10x Visium, MERFISH, DBiTplus, SLIDE-seq, etc.), performs comprehensive biological interpretation including pathway enrichment, cell-cell interaction inference, druggable target identification, immune microenvironment characterization, and multi-modal integration. Produces a detailed markdown report with Spatial Omics Integration Score (0-100), domain-by-domain characterization, and validation recommendations. Uses 70+ ToolUniverse tools across 9 analysis phases. Use when users ask about spatial transcriptomics analysis, spatial omics interpretation, tissue heterogeneity, spatial gene expression patterns, tumor microenvironment mapping, tissue zonation, or cell-cell communication from spatial data.9---1011# Spatial Multi-Omics Analysis Pipeline1213Comprehensive biological interpretation of spatial omics data. Transforms spatially variable genes (SVGs), domain annotations, and tissue context into actionable biological insights covering pathway enrichment, cell-cell interactions, druggable targets, immune microenvironment, and multi-modal integration.1415**KEY PRINCIPLES**:161. **Report-first approach** - Create report file FIRST, then populate progressively172. **Domain-by-domain analysis** - Characterize each spatial region independently before comparison183. **Gene-list-centric** - Analyze user-provided SVGs and marker genes with ToolUniverse databases194. **Biological interpretation** - Go beyond statistics to explain biological meaning of spatial patterns205. **Disease focus** - Emphasize disease mechanisms and therapeutic opportunities when disease context is provided216. **Evidence grading** - Grade all evidence as T1 (human/clinical) to T4 (computational)227. **Multi-modal thinking** - Integrate RNA, protein, and metabolite information when available238. **Validation guidance** - Suggest experimental validation approaches for key findings249. **Source references** - Every statement must cite tool/database source2510. **Completeness checklist** - Mandatory section showing analysis coverage2611. **English-first queries** - Always use English terms in tool calls. Respond in user's language2728---2930## When to Use This Skill3132Apply when users:33- Provide spatially variable genes from spatial transcriptomics experiments34- Ask about biological interpretation of spatial domains/clusters35- Need pathway enrichment analysis of spatial gene expression data36- Want to understand cell-cell interactions from spatial data37- Ask about tumor microenvironment heterogeneity from spatial omics38- Need druggable targets in specific spatial regions39- Ask about tissue zonation patterns (liver, brain, kidney)40- Want to integrate spatial transcriptomics + proteomics data41- Ask about immune infiltration patterns from spatial data42- Need to compare healthy vs disease regions spatially43- Ask "What pathways are enriched in this tumor core vs tumor margin?"44- Ask "What cell-cell interactions occur in this spatial domain?"4546**NOT for** (use other skills instead):47- Single gene interpretation without spatial context -> Use `tooluniverse-target-research`48- Variant interpretation -> Use `tooluniverse-variant-interpretation`49- Drug safety profiling -> Use `tooluniverse-adverse-event-detection`50- Disease-only analysis without spatial data -> Use `tooluniverse-multiomic-disease-characterization`51- GWAS analysis -> Use `tooluniverse-gwas-*` skills52- Bulk RNA-seq (non-spatial) -> Use `tooluniverse-systems-biology`5354---5556## Input Parameters5758| Parameter | Required | Description | Example |59|-----------|----------|-------------|---------|60| **svgs** | Yes | Spatially variable genes (gene symbols) | `['EGFR', 'CDH1', 'VIM', 'MYC', 'CD3E']` |61| **tissue_type** | Yes | Tissue/organ type | `brain`, `liver`, `lung`, `breast`, `skin` |62| **technology** | No | Spatial omics platform used | `10x Visium`, `MERFISH`, `DBiTplus`, `SLIDE-seq` |63| **disease_context** | No | Disease if applicable | `breast cancer`, `Alzheimer disease`, `liver cirrhosis` |64| **spatial_domains** | No | Dict mapping domain name to marker genes | `{'Tumor core': ['MYC','EGFR'], 'Stroma': ['VIM','COL1A1']}` |65| **cell_types** | No | Cell types identified in deconvolution | `['Epithelial', 'T cell', 'Macrophage', 'Fibroblast']` |66| **proteins** | No | Proteins detected (if multi-modal) | `['CD3', 'CD8', 'PD-L1', 'Ki67']` |67| **metabolites** | No | Metabolites detected (if SpatialMETA) | `['glutamine', 'lactate', 'ATP']` |6869---7071## Spatial Omics Integration Score (0-100)7273### Score Components7475**Data Completeness (0-30 points)**:76- SVGs provided (>10 genes): 5 points77- Disease context provided: 5 points78- Spatial domains defined: 5 points79- Cell type composition available: 5 points80- Multi-modal data (protein/metabolite): 5 points81- Literature context found: 5 points8283**Biological Insight (0-40 points)**:84- Significant pathway enrichment (FDR < 0.05): 10 points85- Cell-cell interaction predictions: 10 points86- Disease mechanism identified: 10 points87- Druggable targets found in disease regions: 10 points8889**Evidence Quality (0-30 points)**:90- Cross-database validation (gene found in 3+ databases): 10 points91- Clinical validation (approved drugs for spatial targets): 10 points92- Literature support (PubMed evidence for spatial patterns): 10 points9394### Score Interpretation9596| Score | Tier | Interpretation |97|-------|------|----------------|98| **80-100** | Excellent | Comprehensive spatial characterization, strong biological insights, druggable targets identified |99| **60-79** | Good | Good pathway and interaction analysis, some disease/therapeutic context |100| **40-59** | Moderate | Basic enrichment complete, limited spatial domain comparison or interaction analysis |101| **0-39** | Limited | Minimal data, gene-level annotation only |102103### Evidence Grading System104105| Tier | Symbol | Criteria | Examples |106|------|--------|----------|----------|107| **T1** | [T1] | Direct human evidence, clinical proof | FDA-approved drug for spatial target, validated biomarker |108| **T2** | [T2] | Experimental evidence | Validated spatial pattern in literature, known ligand-receptor pair |109| **T3** | [T3] | Computational/database evidence | PPI network prediction, pathway enrichment, expression correlation |110| **T4** | [T4] | Annotation/prediction only | GO annotation, text-mined association, predicted interaction |111112---113114## Report Template115116Create this file structure at the start: `{tissue}_{disease}_spatial_omics_report.md`117118```markdown119# Spatial Multi-Omics Analysis Report: {Tissue Type}120121**Report Generated**: {date}122**Technology**: {platform}123**Tissue**: {tissue_type}124**Disease Context**: {disease or "Normal tissue"}125**Total SVGs Analyzed**: {count}126**Spatial Domains**: {count}127**Spatial Omics Integration Score**: (to be calculated)128129---130131## Executive Summary132133(2-3 sentence synthesis of key spatial findings - fill after all phases complete)134135---136137## 1. Tissue & Disease Context138139### Tissue Information140| Property | Value | Source |141|----------|-------|--------|142| Tissue type | | |143| Disease | | |144| Expected cell types | | HPA |145146### Disease Identifiers (if applicable)147| System | ID | Source |148|--------|-----|--------|149150**Sources**: (tools used)151152---153154## 2. Spatially Variable Gene Characterization155156### 2.1 Gene ID Resolution157| Gene Symbol | Ensembl ID | Entrez ID | UniProt | Function | Source |158|-------------|------------|-----------|---------|----------|--------|159160### 2.2 Tissue Expression Patterns161| Gene | Tissue Expression | Specificity | Source |162|------|-------------------|-------------|--------|163164### 2.3 Subcellular Localization165| Gene | Location | Confidence | Source |166|------|----------|------------|--------|167168### 2.4 Disease Associations169| Gene | Disease | Score | Evidence | Source |170|------|---------|-------|----------|--------|171172**Sources**: (tools used)173174---175176## 3. Pathway Enrichment Analysis177178### 3.1 STRING Functional Enrichment179| Category | Term | Description | P-value | FDR | Genes | Source |180|----------|------|-------------|---------|-----|-------|--------|181182### 3.2 Reactome Pathway Analysis183| Pathway ID | Name | P-value | FDR | Genes Found | Total Genes | Source |184|------------|------|---------|-----|-------------|-------------|--------|185186### 3.3 GO Biological Processes187| GO Term | Description | P-value | FDR | Genes | Source |188|---------|-------------|---------|-----|-------|--------|189190### 3.4 GO Molecular Functions191| GO Term | Description | P-value | FDR | Genes | Source |192|---------|-------------|---------|-----|-------|--------|193194### 3.5 GO Cellular Components195| GO Term | Description | P-value | FDR | Genes | Source |196|---------|-------------|---------|-----|-------|--------|197198### Pathway Summary199- Top enriched pathways:200- Key biological processes:201- Spatial pathway implications:202203**Sources**: (tools used)204205---206207## 4. Spatial Domain Characterization208209### Domain: {domain_name}210211#### Marker Genes212| Gene | Function | Pathways | Source |213|------|----------|----------|--------|214215#### Enriched Pathways (domain-specific)216| Pathway | P-value | FDR | Genes | Source |217|---------|---------|-----|-------|--------|218219#### Cell Type Signature220| Cell Type | Marker Genes Present | Confidence |221|-----------|---------------------|------------|222223#### Biological Interpretation224(Narrative interpretation of this domain)225226(Repeat for each domain)227228### 4.N Domain Comparison229| Feature | Domain 1 | Domain 2 | Domain 3 |230|---------|----------|----------|----------|231| Top pathway | | | |232| Cell types | | | |233| Disease relevance | | | |234235**Sources**: (tools used)236237---238239## 5. Cell-Cell Interaction Inference240241### 5.1 Protein-Protein Interactions (STRING)242| Protein A | Protein B | Score | Type | Source |243|-----------|-----------|-------|------|--------|244245### 5.2 Ligand-Receptor Pairs246| Ligand | Receptor | Domain (Ligand) | Domain (Receptor) | Evidence | Source |247|--------|----------|-----------------|-------------------|----------|--------|248249### 5.3 Signaling Pathways250| Pathway | Components in Data | Spatial Distribution | Source |251|---------|--------------------|---------------------|--------|252253### 5.4 Interaction Network Summary254- Key interaction hubs:255- Cross-domain interactions:256- Predicted cell-cell communication axes:257258**Sources**: (tools used)259260---261262## 6. Disease & Therapeutic Context263264### 6.1 Disease Gene Overlap265| Gene | Disease Association Score | Evidence Type | Source |266|------|--------------------------|---------------|--------|267268### 6.2 Druggable Targets in Spatial Domains269| Gene | Domain | Tractability | Modality | Approved Drugs | Source |270|------|--------|-------------|----------|----------------|--------|271272### 6.3 Drug Mechanisms Relevant to Spatial Targets273| Drug | Target | Mechanism | Phase | Source |274|------|--------|-----------|-------|--------|275276### 6.4 Clinical Trials277| NCT ID | Title | Target Gene | Phase | Status | Source |278|--------|-------|-------------|-------|--------|--------|279280### Therapeutic Summary281- Druggable genes in disease regions:282- Approved therapies:283- Pipeline drugs:284- Novel opportunities:285286**Sources**: (tools used)287288---289290## 7. Multi-Modal Integration291292### 7.1 Protein-RNA Concordance (if protein data available)293| Gene/Protein | RNA Pattern | Protein Pattern | Concordance | Source |294|-------------|-------------|-----------------|-------------|--------|295296### 7.2 Subcellular Context297| Gene | mRNA Location (spatial) | Protein Location (HPA) | Concordance | Source |298|------|------------------------|----------------------|-------------|--------|299300### 7.3 Metabolic Context (if metabolomics available)301| Gene | Metabolic Pathway | Metabolites Detected | Spatial Pattern | Source |302|------|-------------------|---------------------|-----------------|--------|303304**Sources**: (tools used)305306---307308## 8. Immune Microenvironment (if relevant)309310### 8.1 Immune Cell Markers311| Cell Type | Marker Genes | Spatial Domain | Source |312|-----------|-------------|----------------|--------|313314### 8.2 Immune Checkpoint Expression315| Checkpoint | Gene | Expression Pattern | Source |316|------------|------|--------------------|--------|317318### 8.3 Tumor-Immune Interface (if cancer)319| Feature | Finding | Evidence | Source |320|---------|---------|----------|--------|321322### Immune Summary323- Immune infiltration pattern:324- Key immune checkpoints:325- Immunotherapy implications:326327**Sources**: (tools used)328329---330331## 9. Literature & Validation Context332333### 9.1 Literature Evidence334| PMID | Title | Relevance | Year | Source |335|------|-------|-----------|------|--------|336337### 9.2 Known Spatial Patterns338(Known tissue architecture/zonation from literature)339340### 9.3 Validation Recommendations341| Priority | Gene/Target | Method | Rationale |342|----------|-------------|--------|-----------|343| High | | IHC / smFISH | |344| Medium | | IF / ISH | |345346**Sources**: (tools used)347348---349350## Spatial Omics Integration Score351352| Component | Points | Max | Details |353|-----------|--------|-----|---------|354| SVGs provided | | 5 | |355| Disease context | | 5 | |356| Spatial domains | | 5 | |357| Cell types | | 5 | |358| Multi-modal data | | 5 | |359| Literature context | | 5 | |360| Pathway enrichment | | 10 | |361| Cell-cell interactions | | 10 | |362| Disease mechanism | | 10 | |363| Druggable targets | | 10 | |364| Cross-database validation | | 10 | |365| Clinical validation | | 10 | |366| Literature support | | 10 | |367| **TOTAL** | | **100** | |368369**Score**: XX/100 - [Tier]370371---372373## Completeness Checklist374375- [ ] Gene ID resolution complete376- [ ] Tissue expression patterns analyzed (HPA)377- [ ] Subcellular localization checked (HPA)378- [ ] Pathway enrichment complete (STRING + Reactome)379- [ ] GO enrichment complete (BP + MF + CC)380- [ ] Spatial domains characterized individually381- [ ] Domain comparison performed382- [ ] Protein-protein interactions analyzed (STRING)383- [ ] Ligand-receptor pairs identified384- [ ] Disease associations checked (OpenTargets)385- [ ] Druggable targets identified (OpenTargets tractability)386- [ ] Drug mechanisms reviewed387- [ ] Multi-modal integration performed (if data available)388- [ ] Immune microenvironment characterized (if relevant)389- [ ] Literature search completed390- [ ] Validation recommendations provided391- [ ] Spatial Omics Integration Score calculated392- [ ] Executive summary written393- [ ] All sections have source citations394395---396397## References398399### Data Sources Used400| # | Tool | Parameters | Section | Items Retrieved |401|---|------|------------|---------|-----------------|402403### Database Versions404- OpenTargets: (current)405- STRING: v12.0406- Reactome: (current)407- HPA: (current)408- GTEx: v10409```410411---412413## Phase 0: Input Processing & Disambiguation (ALWAYS FIRST)414415**Objective**: Parse user input, resolve tissue/disease identifiers, establish analysis context.416417### Tools Used418419**OpenTargets_get_disease_id_description_by_name** (if disease context provided):420- **Input**: `diseaseName` (string) - Disease name421- **Output**: `{data: {search: {hits: [{id, name, description}]}}}`422- **Use**: Get MONDO/EFO IDs for disease queries423424**OpenTargets_get_disease_description_by_efoId**:425- **Input**: `efoId` (string) - Disease ID (e.g., `MONDO_0007254`)426- **Output**: `{data: {disease: {id, name, description, dbXRefs}}}`427- **Use**: Get full disease description428429**HPA_search_genes_by_query** (tissue cell type context):430- **Input**: `query` (string) - Search term431- **Output**: List of gene entries matching query432- **Use**: Verify tissue-relevant genes433434### Workflow4354361. Parse SVG list from user input (ensure valid gene symbols)4372. Identify tissue type and map to standard ontology term4383. If disease provided, resolve to MONDO/EFO ID using OpenTargets4394. Get disease description and cross-references4405. Determine analysis scope:441 - Cancer? -> Include immune microenvironment, somatic mutations, druggable targets442 - Neurological? -> Include brain region specificity, neuronal markers443 - Metabolic? -> Include metabolic zonation, enzyme distribution444 - Normal tissue? -> Focus on tissue architecture and cell type composition4456. Set up report file with header information446447### Decision Logic448449- **Cancer tissue**: Enable immune microenvironment phase, CIViC/cBioPortal queries, immuno-oncology analysis450- **Normal tissue**: Skip disease phases, focus on tissue zonation and cell type composition451- **Liver/kidney/brain**: Enable zonation-specific analysis452- **No disease context**: Proceed with tissue biology only453- **Small gene list (<20)**: Warn about limited enrichment power, emphasize gene-level analysis454- **Large gene list (>500)**: Suggest filtering to top SVGs by significance before enrichment455456---457458## Phase 1: Gene Characterization459460**Objective**: Resolve gene identifiers, annotate functions, tissue specificity, and subcellular localization.461462### Tools Used463464**MyGene_query_genes** (gene ID resolution):465- **Input**: `query` (string) - Gene symbol466- **Output**: `{hits: [{_id, symbol, name, ensembl: {gene}, entrezgene}]}`467- **Use**: Resolve gene symbol to Ensembl ID, Entrez ID468- **NOTE**: First hit may not be exact match - filter by `symbol` field469470**UniProt_get_function_by_accession** (gene function):471- **Input**: `accession` (string) - UniProt accession472- **Output**: List of function description strings473- **Use**: Get protein function annotation474475**UniProt_get_subcellular_location_by_accession** (protein localization):476- **Input**: `accession` (string)477- **Output**: Subcellular location information478- **Use**: Where the protein is located in the cell479480**HPA_get_subcellular_location** (validated localization):481- **Input**: `gene_name` (string) - Gene symbol482- **Output**: `{gene_name, main_locations: [], additional_locations: [], location_summary}`483- **Use**: Experimentally validated protein subcellular location484485**HPA_get_rna_expression_by_source** (tissue expression):486- **Input**: `gene_name` (string), `source_type` (string: 'tissue'), `source_name` (string)487- **Output**: `{data: {gene_name, source_type, source_name, expression_value, expression_level}}`488- **Use**: Check expression in the specific tissue of interest489- **NOTE**: All 3 parameters are REQUIRED490491**HPA_get_comprehensive_gene_details_by_ensembl_id** (full HPA data):492- **Input**: `ensembl_id` (string), `include_isoforms` (bool), `include_images` (bool), `include_antibodies` (bool), `include_expression` (bool) - ALL 5 parameters REQUIRED493- **Output**: `{ensembl_id, gene_name, uniprot_ids, summary, protein_classes, tissue_expression, cell_line_expression, ...}`494- **Use**: One-stop gene characterization from HPA495- **NOTE**: Use `include_expression=True` for tissue data; set others to `False` for faster response496497**HPA_get_cancer_prognostics_by_gene** (cancer prognosis):498- **Input**: `ensembl_id` (string) - Ensembl gene ID (NOT gene_name)499- **Output**: `{gene_name, prognostic_cancers_count, prognostic_summary: [{cancer_type, prognostic_type, p_value}]}`500- **Use**: Prognostic significance in cancer (if cancer context)501502**UniProtIDMap_gene_to_uniprot** (ID mapping):503- **Input**: `gene_name` (string), `organism` (string, default 'human')504- **Output**: UniProt accession for the gene505- **Use**: Map gene symbol to UniProt accession506507### Workflow5085091. For each SVG (batch if >20, sample top genes):510 a. Query MyGene to get Ensembl ID, Entrez ID511 b. Map to UniProt accession512 c. Get subcellular location from HPA513 d. Get tissue expression from HPA514 e. If cancer: check cancer prognostics5152. Compile gene characterization table5163. Identify genes with tissue-specific expression5174. Note genes with nuclear vs membrane vs secreted localization (relevant for spatial patterns)518519### Batch Strategy for Large Gene Lists520521- **10-50 genes**: Characterize all individually522- **50-200 genes**: Characterize top 50 by priority (known disease genes first), summarize rest523- **200+ genes**: Characterize top 30, use enrichment for the full list524- Always run pathway enrichment on the FULL list regardless525526---527528## Phase 2: Pathway & Functional Enrichment529530**Objective**: Identify biological pathways and functions enriched in SVGs and per-domain gene sets.531532### Tools Used533534**STRING_functional_enrichment** (primary enrichment):535- **Input**: `protein_ids` (array of gene symbols), `species` (int, 9606 for human)536- **Output**: `{status: 'success', data: [{category, term, number_of_genes, number_of_genes_in_background, p_value, fdr, description, inputGenes, preferredNames}]}`537- **Use**: Comprehensive enrichment across GO, KEGG, Reactome, COMPARTMENTS, DISEASES538- **Categories**: `Process` (GO:BP), `Function` (GO:MF), `Component` (GO:CC), `KEGG`, `Reactome`, `COMPARTMENTS`, `DISEASES`, `Keyword`, `PMID`539- **NOTE**: This is the PRIMARY enrichment tool. Returns all categories in one call540541**ReactomeAnalysis_pathway_enrichment** (Reactome-specific):542- **Input**: `identifiers` (string, space-separated gene symbols, NOT array)543- **Output**: `{data: {token, pathways_found, pathways: [{pathway_id, name, p_value, fdr, entities_found, entities_total}]}}`544- **Use**: Detailed Reactome pathway analysis with hierarchy545- **NOTE**: identifiers is a SPACE-SEPARATED STRING, not array546547**Reactome_map_uniprot_to_pathways** (individual gene):548- **Input**: `id` (string) - UniProt accession549- **Output**: Plain list of pathway objects (no data wrapper)550- **Use**: Map individual proteins to Reactome pathways551552**GO_get_annotations_for_gene** (individual gene GO):553- **Input**: `gene_id` (string) - Gene symbol or ID554- **Output**: Plain list of GO annotation objects555- **Use**: Get GO annotations for individual genes556557**kegg_search_pathway** (KEGG pathway search):558- **Input**: `query` (string) - Pathway name or keyword559- **Output**: Pathway search results560- **Use**: Find KEGG pathways relevant to spatial findings561562**WikiPathways_search** (WikiPathways):563- **Input**: `query` (string) - Search term564- **Output**: WikiPathways search results565- **Use**: Additional pathway context566567### Workflow5685691. **Global SVG enrichment**: Run STRING_functional_enrichment on ALL SVGs570 - Filter results by FDR < 0.05571 - Separate by category (Process, Function, Component, KEGG, Reactome)572 - Report top 10-15 per category5732. **Reactome detailed analysis**: Run ReactomeAnalysis_pathway_enrichment574 - Report top pathways with FDR < 0.055753. **Per-domain enrichment** (if spatial domains provided):576 - Run STRING_functional_enrichment on each domain's gene set577 - Compare enriched pathways across domains578 - Identify domain-specific vs shared pathways5794. **Compile pathway tables**: Merge results from all enrichment tools580581### Enrichment Interpretation582583- **Signaling pathways** (RTK, Wnt, Notch, Hedgehog): Cell-cell communication584- **Metabolic pathways**: Tissue metabolic zonation585- **Immune pathways**: Immune infiltration/exclusion586- **ECM/adhesion pathways**: Tissue structure and remodeling587- **Cell cycle/proliferation**: Growth zones588- **Apoptosis/stress**: Damage zones589590---591592## Phase 3: Spatial Domain Characterization593594**Objective**: Characterize each spatial domain biologically and compare between domains.595596### Tools Used597598Uses the same tools as Phase 2 (STRING_functional_enrichment, ReactomeAnalysis) applied per-domain, plus:599600**HPA_get_biological_processes_by_gene** (per-gene processes):601- **Input**: `gene_name` (string)602- **Output**: Biological processes associated with the gene603- **Use**: Annotate domain marker genes604605**HPA_get_protein_interactions_by_gene** (gene interactions):606- **Input**: `gene_name` (string)607- **Output**: Known protein interaction partners608- **Use**: Build domain-specific interaction context609610### Workflow6116121. For each spatial domain:613 a. Get marker gene list614 b. Run STRING_functional_enrichment on domain genes615 c. Identify top pathways, GO terms616 d. Assign likely cell type(s) based on marker genes:617 - Epithelial: CDH1, EPCAM, KRT18, KRT19618 - Mesenchymal/Fibroblast: VIM, COL1A1, COL3A1, FAP, ACTA2619 - Immune T cell: CD3E, CD3D, CD4, CD8A, CD8B620 - Immune B cell: CD19, CD20 (MS4A1), CD79A621 - Macrophage: CD68, CD163, CSF1R622 - Endothelial: PECAM1, VWF, CDH5623 - Neuronal: SNAP25, SYP, MAP2, NEFL624 - Hepatocyte: ALB, HNF4A, CYP3A4625 e. Generate biological interpretation narrative6262. Compare domains:627 - Differential pathways628 - Unique vs shared genes629 - Disease-relevant vs homeostatic regions630 - Transition zones (shared genes between adjacent domains)631632### Cell Type Assignment Rules633634When user does not provide cell type annotations, infer from marker genes:635- Check each gene against known cell type markers636- Use HPA tissue/cell type expression data for validation637- Report confidence level (high: 3+ markers match, medium: 2 markers, low: 1 marker)638639---640641## Phase 4: Cell-Cell Interaction Inference642643**Objective**: Predict cell-cell communication from spatial gene expression patterns.644645### Tools Used646647**STRING_get_interaction_partners** (PPI network):648- **Input**: `protein_ids` (array), `species` (int, 9606), `limit` (int), `confidence_score` (float, 0.7)649- **Output**: `{status: 'success', data: [{preferredName_A, preferredName_B, score, nscore, fscore, pscore, ascore, escore, dscore, tscore}]}`650- **Use**: Find protein-protein interactions among SVGs651- **Score types**: nscore=neighborhood, fscore=fusion, pscore=phylogenetic, ascore=coexpression, escore=experimental, dscore=database, tscore=textmining652653**STRING_get_protein_interactions** (pairwise interactions):654- **Input**: `protein_ids` (array), `species` (int, 9606)655- **Output**: Interaction data between specified proteins656- **Use**: Get interactions within a specific gene set657658**intact_search_interactions** (IntAct database):659- **Input**: `query` (string), `max` (int)660- **Output**: Interaction data from IntAct661- **Use**: Complement STRING with IntAct interactions662663**Reactome_get_interactor** (Reactome interactions):664- **Input**: Protein/gene identifier665- **Output**: Reactome interaction data666- **Use**: Pathway-level interaction context667668**DGIdb_get_drug_gene_interactions** (drug-gene interactions):669- **Input**: `genes` (array of strings)670- **Output**: Drug-gene interaction data671- **Use**: Identify druggable interaction nodes672673### Ligand-Receptor Analysis674675Known ligand-receptor pairs to check in SVG list:676- **Growth factors**: EGF-EGFR, HGF-MET, VEGF-KDR, FGF-FGFR, PDGF-PDGFRA/B677- **Cytokines**: TNF-TNFR, IL6-IL6R, IFNG-IFNGR, TGFB1-TGFBR1/2678- **Chemokines**: CXCL12-CXCR4, CCL2-CCR2, CXCL10-CXCR3679- **Immune checkpoints**: CD274(PD-L1)-PDCD1(PD-1), CD80/CD86-CTLA4, LGALS9-HAVCR2(TIM-3)680- **Notch signaling**: DLL1/3/4-NOTCH1/2/3/4, JAG1/2-NOTCH1/2681- **Wnt signaling**: WNT ligands-FZD receptors682- **Adhesion**: CDH1-CDH1 (homotypic), ITGA/B integrins-ECM683- **Hedgehog**: SHH-PTCH1684685### Workflow6866871. Run STRING_get_interaction_partners on all SVGs688 - Filter interactions with score > 0.7689 - Identify hub genes (most connections)6902. Check for known ligand-receptor pairs in gene list691 - Cross-reference with spatial domain assignments692 - Identify potential cross-domain signaling6933. Build interaction network:694 - Intra-domain interactions (within same spatial region)695 - Inter-domain interactions (between different regions)696 - Identify signaling axes (e.g., tumor-stroma, immune-tumor)6974. Map interactions to Reactome signaling pathways698699---700701## Phase 5: Disease & Therapeutic Context702703**Objective**: Connect spatial findings to disease mechanisms and identify druggable targets.704705### Tools Used706707**OpenTargets_get_associated_targets_by_disease_efoId** (disease genes):708- **Input**: `efoId` (string), `size` (int)709- **Output**: `{data: {disease: {associatedTargets: {count, rows: [{target: {id, approvedSymbol}, score}]}}}}`710- **Use**: Get disease-associated genes, overlap with SVGs711712**OpenTargets_get_target_tractability_by_ensemblID** (druggability):713- **Input**: `ensemblId` (string)714- **Output**: Tractability data (small molecule, antibody, other modalities)715- **Use**: Assess if spatial targets are druggable716717**OpenTargets_get_associated_drugs_by_target_ensemblID** (drugs for target):718- **Input**: `ensemblId` (string), `size` (int)719- **Output**: Drug data for the target720- **Use**: Find approved/clinical drugs targeting spatial genes721722**OpenTargets_get_drug_mechanisms_of_action_by_chemblId** (drug mechanism):723- **Input**: `chemblId` (string)724- **Output**: Mechanism of action data725- **Use**: Understand how drugs act on spatial targets726727**OpenTargets_target_disease_evidence** (evidence linking target to disease):728- **Input**: `ensemblId` (string), `efoId` (string)729- **Output**: Evidence items linking target to disease730- **Use**: Specific evidence for each spatial gene in disease731732**clinical_trials_search** (clinical trials):733- **Input**: `action` = `"search_studies"`, `condition` (string), `intervention` (string), `limit` (int)734- **Output**: `{total_count, studies: [{nctId, title, status, conditions}]}`735- **Use**: Find clinical trials for spatial targets736- **NOTE**: `action` MUST be `"search_studies"`737738**DGIdb_get_gene_druggability** (druggability categories):739- **Input**: `genes` (array of strings)740- **Output**: `{data: {genes: {nodes: [{name, geneCategories: [{name}]}]}}}`741- **Use**: Classify genes as druggable, kinase, GPCR, etc.742743**civic_search_genes** (CIViC cancer evidence, if cancer):744- **Input**: (no filter by name)745- **Output**: Gene list from CIViC746- **Use**: Check if SVGs have CIViC clinical evidence747748### Workflow7497501. **Disease gene overlap** (if disease context provided):751 a. Get disease-associated targets from OpenTargets752 b. Intersect with SVGs753 c. For overlapping genes, get specific evidence7542. **Druggable target identification**:755 a. Run DGIdb_get_gene_druggability on all SVGs756 b. For druggable genes, check OpenTargets tractability757 c. Get approved drugs for druggable spatial targets7583. **Clinical trials**:759 a. Search for trials targeting spatial genes in the disease context760 b. Prioritize trials for genes in disease-enriched spatial domains7614. **Cancer-specific** (if cancer):762 a. Check CIViC for clinical evidence763 b. Get mutation prevalence from cBioPortal (if specific mutations known)764 c. Check immune checkpoint genes in spatial data765766---767768## Phase 6: Multi-Modal Integration769770**Objective**: Integrate protein, RNA, and metabolite spatial data when available.771772### Tools Used773774**HPA_get_subcellular_location** (protein localization):775- **Input**: `gene_name` (string)776- **Output**: `{gene_name, main_locations, additional_locations, location_summary}`777- **Use**: Compare mRNA spatial pattern with protein subcellular location778779**HPA_get_rna_expression_in_specific_tissues** (tissue RNA):780- **Input**: `ensembl_id` (string), `tissue_name` (string)781- **Output**: Expression data for specific tissue782- **Use**: Validate spatial expression against bulk tissue data783784**Reactome_map_uniprot_to_pathways** (metabolic pathways):785- **Input**: `id` (string) - UniProt accession786- **Output**: List of pathways787- **Use**: Map genes to metabolic pathways for metabolomics integration788789**kegg_get_pathway_info** (KEGG pathway details):790- **Input**: `pathway_id` (string) - KEGG pathway ID791- **Output**: Pathway information including metabolites792- **Use**: Link spatial genes to metabolic pathways and metabolites793794### Workflow7957961. **RNA-Protein concordance** (if protein data provided):797 a. For each gene with both RNA and protein data:798 - Compare spatial RNA pattern with protein detection799 - Check HPA for known post-transcriptional regulation800 - Note concordant (expected) vs discordant (interesting) patterns8012. **Subcellular context**:802 a. Map spatial RNA localization to protein subcellular location (HPA)803 b. Secreted proteins -> likely paracrine signaling804 c. Membrane proteins -> cell surface markers805 d. Nuclear proteins -> transcription factors8063. **Metabolic integration** (if metabolomics available):807 a. Map genes to metabolic pathways (Reactome, KEGG)808 b. Link detected metabolites to enzyme-encoding genes809 c. Identify spatial metabolic heterogeneity810 d. Check for known metabolic zonation patterns811812---813814## Phase 7: Immune Microenvironment (Cancer/Inflammation)815816**Objective**: Characterize immune cell composition and checkpoint expression in spatial context.817818### Conditions for Activation819820Only execute if:821- Disease context is cancer, autoimmune, or inflammatory822- SVGs include immune markers (CD3E, CD8A, CD68, CD163, etc.)823- User specifically asks about immune patterns824825### Tools Used826827**STRING_functional_enrichment** (immune pathway enrichment):828- Applied to immune-relevant SVGs829- Filter for immune-related GO terms and pathways830831**OpenTargets_get_target_tractability_by_ensemblID** (checkpoint druggability):832- Applied to immune checkpoint genes833- Check for approved immunotherapies834835**iedb_search_epitopes** (epitope data):836- **Input**: `organism_name` (string), `source_antigen_name` (string)837- **Output**: `{status, data, count}`838- **Use**: Check if spatial antigens have known epitopes839840### Immune Cell Markers Reference841842| Cell Type | Key Markers | Extended Markers |843|-----------|-------------|-----------------|844| CD8+ T cell | CD8A, CD8B | GZMA, GZMB, PRF1, IFNG |845| CD4+ T cell | CD4 | IL2, IL4, IL17A, FOXP3 (Treg) |846| Regulatory T cell | FOXP3, IL2RA | CTLA4, TIGIT |847| B cell | CD19, MS4A1, CD79A | IGHG1, IGHM |848| Plasma cell | SDC1 (CD138), XBP1 | IGHG1, MZB1 |849| M1 Macrophage | CD68, NOS2, TNF | IL1B, CXCL10 |850| M2 Macrophage | CD68, CD163, MRC1 | ARG1, IL10 |851| Dendritic cell | ITGAX (CD11c), HLA-DRA | CD80, CD86 |852| NK cell | NCAM1 (CD56), NKG7 | GNLY, KLRD1 |853| Neutrophil | FCGR3B, CXCR2 | S100A8, S100A9 |854| Mast cell | KIT, TPSAB1 | CPA3, HDC |855856### Immune Checkpoint Reference857858| Checkpoint | Gene | Ligand | Therapeutic Antibody |859|------------|------|--------|---------------------|860| PD-1/PD-L1 | PDCD1/CD274 | CD274, PDCD1LG2 | Pembrolizumab, Nivolumab, Atezolizumab |861| CTLA-4 | CTLA4 | CD80, CD86 | Ipilimumab |862| TIM-3 | HAVCR2 | LGALS9 | Sabatolimab |863| LAG-3 | LAG3 | HLA class II | Relatlimab |864| TIGIT | TIGIT | PVR, PVRL2 | Tiragolumab |865| VISTA | VSIR | PSGL1 | - |866867### Workflow8688691. Identify immune-related SVGs from marker reference8702. Classify immune cell types present per spatial domain8713. Check immune checkpoint expression8724. Assess immune infiltration patterns:873 - Hot (T cell infiltrated) vs Cold (immune desert) vs Excluded8745. Identify potential immunotherapy targets8756. Check for tertiary lymphoid structures (B cell + T cell clusters)876877---878879## Phase 8: Literature & Validation Context880881**Objective**: Provide literature evidence for spatial findings and suggest validation experiments.882883### Tools Used884885**PubMed_search_articles** (literature search):886- **Input**: `query` (string), `max_results` (int)887- **Output**: List of `[{pmid, title, authors, journal, pub_date, doi}]`888- **Use**: Find published evidence for spatial patterns889890**openalex_literature_search** (broader literature):891- **Input**: `query` (string), `per_page` (int)892- **Output**: List of works with titles, DOIs, abstracts893- **Use**: Complement PubMed with preprints and broader coverage894895### Literature Search Strategy8968971. **Tissue + spatial**: `"{tissue} spatial transcriptomics"` - e.g., "liver spatial transcriptomics"8982. **Disease + spatial**: `"{disease} spatial omics"` - e.g., "breast cancer spatial transcriptomics"8993. **Gene + tissue**: `"{top_gene} {tissue} expression"` for key SVGs9004. **Zonation** (if relevant): `"{tissue} zonation gene expression"`9015. **Technology**: `"{technology} {tissue}"` - e.g., "Visium breast cancer"902903### Validation Recommendations Template904905| Priority | Target | Method | Rationale | Feasibility |906|----------|--------|--------|-----------|-------------|907| **High** | Key SVG | smFISH / RNAscope | Validate spatial pattern at single-molecule level | Medium |908| **High** | Druggable target | IHC on serial sections | Confirm protein expression in spatial domain | High |909| **High** | Ligand-receptor pair | Proximity ligation assay (PLA) | Confirm physical interaction at tissue level | Medium |910| **Medium** | Domain markers | Multiplexed IF (CODEX/IBEX) | Validate multiple markers simultaneously | Low-Medium |911| **Medium** | Pathway | Spatial metabolomics (MALDI/DESI) | Confirm metabolic pathway activity | Low |912| **Low** | Novel interaction | Co-culture + conditioned media | Functional validation of predicted interaction | Medium |913914### Workflow9159161. Search PubMed for tissue + disease + spatial transcriptomics9172. Search for known spatial patterns in the tissue type9183. Cross-reference findings with published spatial atlas data9194. Generate validation recommendations based on:920 - Novelty of finding (novel patterns need more validation)921 - Clinical relevance (druggable targets prioritized)922 - Technical feasibility9235. Cite relevant methodology papers for each validation approach924925---926927## Tool Parameter Reference (CRITICAL)928929### Verified Parameter Names930931| Tool | Parameter | CORRECT | Common MISTAKE | Notes |932|------|-----------|---------|----------------|-------|933| `MyGene_query_genes` | query | `query` | `q` | Filter results by `symbol` field |934| `STRING_functional_enrichment` | identifiers | `protein_ids` (array) | `identifiers` | Also needs `species=9606` |935| `STRING_get_interaction_partners` | identifiers | `protein_ids` (array) | `identifiers` | `limit`, `confidence_score` optional |936| `ReactomeAnalysis_pathway_enrichment` | genes | `identifiers` (string) | Array | SPACE-SEPARATED string, NOT array |937| `HPA_get_subcellular_location` | gene | `gene_name` | `ensembl_id` | Uses gene symbol |938| `HPA_get_cancer_prognostics_by_gene` | gene | `ensembl_id` | `gene_name` | Uses Ensembl ID, NOT symbol |939| `HPA_get_rna_expression_by_source` | params | `gene_name`, `source_type`, `source_name` | - | ALL 3 required |940| `HPA_get_rna_expression_in_specific_tissues` | gene | `ensembl_id` | `gene_name` | Uses Ensembl ID |941| `OpenTargets_get_target_tractability_by_ensemblID` | target | `ensemblId` | `ensemblID` | camelCase |942| `OpenTargets_get_associated_drugs_by_target_ensemblID` | target | `ensemblId`, `size` | - | Both REQUIRED |943| `OpenTargets_get_associated_targets_by_disease_efoId` | disease | `efoId` | `diseaseId` | Returns {data: {disease: {associatedTargets}}} |944| `DGIdb_get_gene_druggability` | genes | `genes` (array) | `gene_name` | Array of strings |945| `DGIdb_get_drug_gene_interactions` | genes | `genes` (array) | `gene_name` | Array of strings |946| `clinical_trials_search` | action | `action='search_studies'` | Missing action | `action` is REQUIRED |947| `ensembl_lookup_gene` | species | `species='homo_sapiens'` | No species | REQUIRED parameter |948| GTEx tools | operation | `operation` (SOAP) | Missing | All GTEx tools need `operation` parameter |949| `HPA_get_comprehensive_gene_details_by_ensembl_id` | all params | ALL 5 required: `ensembl_id`, `include_isoforms`, `include_images`, `include_antibodies`, `include_expression` | Missing booleans | Set booleans to False except expression |950| GTEx tools | gencode | `gencode_id` (array) | `gene_id` | Requires versioned GENCODE ID |951952### Response Format Reference953954| Tool | Response Format | Key Fields |955|------|----------------|------------|956| `STRING_functional_enrichment` | `{status, data: [{category, term, description, p_value, fdr, inputGenes}]}` | Filter by FDR < 0.05 |957| `ReactomeAnalysis_pathway_enrichment` | `{data: {pathways: [{pathway_id, name, p_value, fdr, entities_found, entities_total}]}}` | Top 20 returned |958| `STRING_get_interaction_partners` | `{status, data: [{preferredName_A, preferredName_B, score}]}` | Score > 0.7 for high confidence |959| `MyGene_query_genes` | `{hits: [{_id, symbol, name, ensembl: {gene}, entrezgene}]}` | Filter by exact symbol match |960| `HPA_get_subcellular_location` | `{gene_name, main_locations: [], additional_locations: [], location_summary}` | Dire961962…(truncated)